{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T05:57:16Z","timestamp":1772344636114,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dallas Fort Worth Living Legend Professorship"},{"name":"NCI","award":["R01CA288515"],"award-info":[{"award-number":["R01CA288515"]}]},{"name":"NCI","award":["R01CA214960"],"award-info":[{"award-number":["R01CA214960"]}]},{"name":"NCI","award":["R01CA231471"],"award-info":[{"award-number":["R01CA231471"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Introduction: Prescription monitoring programs (PMPs) are commonly used to monitor non-medical opioid use (NMOU); however, the effectiveness of PMPs for identifying cancer patients with risk factors is not well known. Methods: This study assessed the frequency and predictors of concerning PMP findings among cancer patients in a palliative care clinic and examined the ability of PMPs, clinical review, and urine drug testing to identify NMOU behaviors. This was a retrospective analysis of consecutive cancer patients seen by palliative care at a safety-net hospital over four years. Demographic, clinical, and psychosocial risk factors for NMOU were extracted from the medical record. Concerning PMP findings were based on prescriber documentation. Logistic regression models identified predictors of documented PMP concerns. Results: Among 906 patients, 844 (93%) had PMP reviews at either consultation or a follow-up visit. Of these, 31\/844 (4%) demonstrated documented PMP concern. Predictors of documented PMP irregularities included a history of illicit drug use (OR 6.30, 95% CI: 2.35\u201317.06), opioid use for non-malignant pain (OR 19.49, 95% CI: 6.24\u201360.90), and a family history of illicit drug use (OR 5.42, 95% CI: 0.96\u201325.04). Discussion: A total of 166 patients (20%) were identified as having NMOU behaviors based on clinical review; in contrast, PMP review identified only 31 (4%) patients with NMOU behaviors, and two (6%) were missed by clinical review. Documented PMP concern was low in cancer patients. Clinical review identified most patients with NMOU behaviors, with limited contribution from PMP review. Our findings suggest that PMP should not be used in isolation when assessing opioid-related risk in this population.<\/jats:p>","DOI":"10.3390\/cancers18050762","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:31:19Z","timestamp":1772181079000},"page":"762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescription Monitoring Program Review Among Patients with Cancer Receiving Opioids at a Safety-Net Palliative Medicine Clinic"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-0258","authenticated-orcid":false,"given":"Soraira","family":"Pacheco","sequence":"first","affiliation":[{"name":"Joan and Stanford Alexander Division of Geriatric and Palliative Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linh M. T.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Joan and Stanford Alexander Division of Geriatric and Palliative Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Arthur","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Rehabilitation and Integrative Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Manuel","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-6607","authenticated-orcid":false,"given":"David","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Rehabilitation and Integrative Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA"},{"name":"Center for Goal Concordant Care Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"},{"name":"Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.19.00470","article-title":"Palliative Care and the Management of Common Distressing Symptoms in Advanced Cancer: Pain, Breathlessness, Nausea and Vomiting, and Fatigue","volume":"38","author":"Henson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/curroncol28010086","article-title":"Managing Opioids and Mitigating Risk: A Survey of Attitudes, Confidence and Practices of Oncology Health Care Professionals","volume":"28","author":"Tedesco","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/oncolo\/oyad214","article-title":"Opioid Risk Mitigation Practices of Interprofessional Oncology Personnel: Results from a Cross-Sectional Survey","volume":"28","author":"McNally","year":"2023","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/08897077.2019.1692122","article-title":"Beneficial Opioid Management Strategies: A Review of the Evidence for the Use of Opioid Treatment Agreements","volume":"41","author":"Palombi","year":"2020","journal-title":"Subst. Abus."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41571-018-0143-7","article-title":"Balancing Opioid Analgesia with the Risk of Nonmedical Opioid Use in Patients with Cancer","volume":"16","author":"Arthur","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.22.02198","article-title":"Use of Opioids for Adults with Pain from Cancer or Cancer Treatment: ASCO Guideline","volume":"41","author":"Paice","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/j.jpainsymman.2025.07.002","article-title":"Impact of Patient Prescriber Agreement on Aberrant Urine Drug Tests Among Patients Receiving Opioids for Cancer Pain","volume":"70","author":"Arthur","year":"2025","journal-title":"J. Pain Symptom Manag."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1634\/theoncologist.2019-0540","article-title":"Best Practices in the Management of Nonmedical Opioid Use in Patients with Cancer-Related Pain","volume":"25","author":"Ulker","year":"2020","journal-title":"Oncologist"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMp2211040","article-title":"Prescribing Opioids for Pain\u2014The New CDC Clinical Practice Guideline","volume":"387","author":"Dowell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain","volume":"10","author":"Chou","year":"2009","journal-title":"J. Pain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.7326\/0003-4819-160-1-201401070-00732","article-title":"Opioid Prescribing: A Systematic Review and Critical Appraisal of Guidelines for Chronic Pain","volume":"160","author":"Nuckols","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pacheco, S., Nguyen, L.M.T., Halphen, J.M., Samy, N.N., Wilson, N.R., Sattler, G., Wing, S.E., Feng, C., Paulino, R.A.D., and Shah, P. (2023). Adherence to Opioid Patient Prescriber Agreements at a Safety Net Hospital. Cancers, 15.","DOI":"10.3390\/cancers15112943"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Halphen, J.M., Arthur, J.A., Pacheco, S., Nguyen, L.M.T., Samy, N.N., Wilson, N.R., Sattler, G., Wing, S.E., Paulino, R.A.D., and Feng, C. (2023). Immunoassay Urine Drug Testing among Patients Receiving Opioids at a Safety-Net Palliative Medicine Clinic. Cancers, 15.","DOI":"10.20944\/preprints202309.0011.v1"},{"key":"ref_14","unstructured":"D\u2019Souza, R.S., Lang, M., and Eldrige, J.S. (2025). Prescription Drug Monitoring Program. StatPearls, StatPearls Publishing."},{"key":"ref_15","unstructured":"(2025, November 14). Prescription Drug Monitoring Program Training and Technical Assistance Center. Available online: https:\/\/www.pdmpassist.org\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/epirev\/mxaa002","article-title":"Prescription Drug Monitoring Programs and Prescription Opioid\u2013Related Outcomes in the United States","volume":"42","author":"Chihuri","year":"2020","journal-title":"Epidemiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/01612840.2011.654046","article-title":"Prescription Drug Monitoring Programs, a Response to Doctor Shopping: Purpose, Effectiveness, and Directions for Future Research","volume":"33","author":"Worley","year":"2012","journal-title":"Issues Ment. Health Nurs."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12913-017-2354-5","article-title":"Evaluating the Impact of Prescription Drug Monitoring Program Implementation: A Scoping Review","volume":"17","author":"Finley","year":"2017","journal-title":"BMC Health Serv. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addbeh.2017.01.011","article-title":"Prescription Drug Monitoring Programs, Nonmedical Use of Prescription Drugs, and Heroin Use: Evidence from the National Survey of Drug Use and Health","volume":"69","author":"Ali","year":"2017","journal-title":"Addict. Behav."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107563","DOI":"10.1016\/j.drugalcdep.2019.107563","article-title":"Evidence for State, Community and Systems-Level Prevention Strategies to Address the Opioid Crisis","volume":"204","author":"Haegerich","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Picco, L., Jung, M., Cangadis-Douglass, H., Lam, T., and Nielsen, S. (2023). Identifying Prescription-Opioid-Related Risks Using Prescription Drug Monitoring Programs\u2019 Algorithms and Clinical Screening Tools. Pharmacy, 11.","DOI":"10.3390\/pharmacy11050164"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.21037\/apm-23-404","article-title":"Impact of Mandated Drug Monitoring on Opioid Use during Highly Conformal Radiotherapy for Oropharynx Cancer","volume":"12","author":"Gracie","year":"2023","journal-title":"Ann. Palliat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamaoncol.2020.0804","article-title":"Association of Mandatory-Access Prescription Drug Monitoring Programs with Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist","volume":"6","author":"Graetz","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/jpm.2020.0537","article-title":"Deficiencies with the Use of Prescription Drug Monitoring Program in Cancer Pain Management: A Report of Two Cases","volume":"24","author":"Tang","year":"2021","journal-title":"J. Palliat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jama.2021.10161","article-title":"Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients with Sickle Cell Disease or Cancer with Bone Metastasis","volume":"326","author":"Zhang","year":"2021","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11003","DOI":"10.1200\/JCO.2024.42.16_suppl.11003","article-title":"Prescription Drug Monitoring Program Mandates and Opioid Prescriptions Received by Patients Dying of Cancer","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"pkad006","DOI":"10.1093\/jncics\/pkad006","article-title":"The Effect of Cancer Exemption in Mandatory-Access Prescription Drug Monitoring Programs among Oncologists","volume":"7","author":"Graetz","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_28","first-page":"135","article-title":"Conjoint Screening Questionnaires for Alcohol and Other Drug Abuse: Criterion Validity in a Primary Care Practice","volume":"94","author":"Brown","year":"1995","journal-title":"Wis. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments","volume":"53","author":"Hui","year":"2017","journal-title":"J. Pain Symptom Manag."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.mayocp.2021.05.005","article-title":"Medical Cannabis State and Federal Regulations: Implications for United States Health Care Entities","volume":"96","author":"Perlman","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/acem.13352","article-title":"Past-year Prescription Drug Monitoring Program Opioid Prescriptions and Self-reported Opioid Use in an Emergency Department Population with Opioid Use Disorder","volume":"25","author":"Hawk","year":"2018","journal-title":"Acad. Emerg. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ajem.2019.05.035","article-title":"The Utility of a Statewide Prescription Drug-Monitoring Database vs the Current Opioid Misuse Measure for Identifying Drug-Aberrant Behaviors in Emergency Department Patients Already on Opioids","volume":"38","author":"Wilson","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"ref_33","first-page":"pkad006","article-title":"Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Swarm","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1475-6773.13968","article-title":"Did Prescribing Laws Disproportionately Affect Opioid Dispensing to Black Patients?","volume":"57","author":"Townsend","year":"2022","journal-title":"Health Serv. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.22.01413","article-title":"Racial and Ethnic Disparities in Opioid Access and Urine Drug Screening Among Older Patients with Poor-Prognosis Cancer Near the End of Life","volume":"41","author":"Enzinger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1245\/s10434-023-14218-4","article-title":"Association of Race\/Ethnicity, Persistent Poverty, and Opioid Access Among Patients with Gastrointestinal Cancer Near the End of Life","volume":"30","author":"Munir","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1097\/NCC.0000000000001197","article-title":"A Qualitative Study of the Pain Experience of Black Individuals with Cancer Taking Long-Acting Opioids","volume":"47","author":"Yeager","year":"2024","journal-title":"Cancer Nurs."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/1055-9965.EPI-23-0251","article-title":"Unraveling Racial Disparities in Supportive Care Medication Use among End-of-Life Pancreatic Cancer Patients: Focus on Pain Management and Psychiatric Therapies","volume":"32","author":"Allen","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/pm\/pnab344","article-title":"Defining \u201cDoctor Shopping\u201d with Dispensing Data: A Scoping Review","volume":"23","author":"Delcher","year":"2022","journal-title":"Pain Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1097\/PR9.0000000000000955","article-title":"Doctor Shopping among Chronic Noncancer Pain Patients Treated with Opioids in the Province of Quebec (Canada): Incidence, Risk Factors, and Association with the Occurrence of Opioid Overdoses","volume":"6","author":"Dassieu","year":"2021","journal-title":"Pain Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2147\/JPR.S203350","article-title":"Medical Record-Based Ascertainment of Behaviors Suggestive of Opioid Misuse, Diversion, Abuse, and\/or Addiction among Individuals Showing Evidence of Doctor\/Pharmacy Shopping","volume":"12","author":"Esposito","year":"2019","journal-title":"J. Pain Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1595953","DOI":"10.1080\/20016689.2019.1595953","article-title":"Characteristics of Doctor-Shoppers: A Systematic Literature Review","volume":"7","author":"Biernikiewicz","year":"2019","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drugalcdep.2015.12.007","article-title":"A Comparison of an Opioid Abuse Screening Tool and Prescription Drug Monitoring Data in the Emergency Department","volume":"159","author":"Weiner","year":"2016","journal-title":"Drug Alcohol Depend."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T05:12:29Z","timestamp":1772341949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050762"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050762","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}